Live-attenuated respiratory syncytial virus vaccines

Ruth A. Karron, Ursula J. Buchholz, Peter L. Collins

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.

Original languageEnglish (US)
Title of host publicationChallenges and Opportunities for Respiratory Syncytial Virus Vaccines
EditorsLarry Anderson, Barney Graham
Pages259-284
Number of pages26
DOIs
StatePublished - Dec 1 2013

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume372
ISSN (Print)0070-217X

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Live-attenuated respiratory syncytial virus vaccines'. Together they form a unique fingerprint.

Cite this